This company has been marked as potentially delisted and may not be actively trading. Intercept Pharmaceuticals (ICPT) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock ICPT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Intercept Announces Data to be Presented at Digestive Disease Week 2025April 30, 2025 | finance.yahoo.comIntercept loses Ocaliva FDA full approval bid in rare liver diseaseNovember 13, 2024 | msn.comUS FDA declines full approval for Intercept's liver disease drugNovember 12, 2024 | reuters.comIntercept Receives Complete Response Letter from FDA Addressing OCALIVA supplemental New Drug Application (sNDA)November 12, 2024 | globenewswire.comIntercept’s liver disease drug Ocaliva faces FDA approval delayOctober 19, 2024 | msn.comIntercept Provides Regulatory Update Regarding sNDA for OCALIVAOctober 17, 2024 | finance.yahoo.comFDA advisers vote against confirmatory data for Intercept's liver disease drugSeptember 13, 2024 | reuters.comFDA staff raises efficacy concerns over Intercept's liver disease drugSeptember 11, 2024 | reuters.comFindings From COBALT Trial, Including External Control Arm, Published in The American Journal of GastroenterologySeptember 6, 2024 | finance.yahoo.comIntercept Announces New Data to be Presented at the European Association for the Study of the Liver (EASL) Congress 2024May 29, 2024 | finance.yahoo.com89bio gains 47% on topline data for NASH candidateMarch 21, 2024 | msn.comIntercept Announces FDA Acceptance of Supplemental New Drug Application for Ocaliva® (obeticholic acid) for the Treatment of PBCFebruary 29, 2024 | globenewswire.comIntercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage at AASLD The Liver Meeting® 2023November 13, 2023 | finance.yahoo.comIntercept Announces New Findings from Long-term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD The Liver Meeting® 2023November 10, 2023 | finance.yahoo.comIntercept Pharmaceuticals (Nasdaq:ICPT) HeadlineTrading was temporarily halted for "ICPT" at 07:11 PM with a stated reason of "News pending."...November 8, 2023 | marketbeat.comAlfasigma S.p.A. successfully completes tender offer for all outstanding shares of common stock of Intercept Pharmaceuticals, Inc.November 8, 2023 | finance.yahoo.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 6.63% to 19.38November 2, 2023 | msn.comWill Intercept Pharmaceuticals (ICPT) Report Negative Q3 Earnings? What You Should KnowOctober 31, 2023 | finance.yahoo.comStocks to Sell: 7 Overbought Companies You Ought to Dump Right NowOctober 27, 2023 | finance.yahoo.comIntercept Pharmaceuticals (NASDAQ:ICPT) shareholders have endured a 83% loss from investing in the stock five years agoOctober 11, 2023 | finance.yahoo.comIntercept Pharmaceuticals (ICPT) Price Target Increased by 21.49% to 18.17October 5, 2023 | msn.comIntercept Pharma unlikely to see rival offers, other roadblocks, analysts saySeptember 28, 2023 | msn.comCanaccord Genuity Downgrades Intercept Pharmaceuticals (ICPT)September 28, 2023 | msn.comRoyal Bank of Canada Increases Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target to $19.00September 27, 2023 | marketbeat.comIntercept Pharma Acquisition by Alfasigma: A Strategic Move and Fair Value AssessmentSeptember 27, 2023 | markets.businessinsider.comIntercept Pharmaceuticals stock soars on Alfasigma acquisition dealSeptember 27, 2023 | proactiveinvestors.comCanaccord cuts Intercept to hold, calls Alfasigma deal "best possible outcome"September 26, 2023 | msn.comShareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with AlfasigmaSeptember 26, 2023 | benzinga.comIntercept Pharmaceuticals: Alfasigma Pays Premium For M&A Deal That Suits All PartiesSeptember 26, 2023 | seekingalpha.comWhy Is Intercept Pharmaceuticals (ICPT) Stock Up 75% Today?September 26, 2023 | investorplace.comIntercept Pharma Shares Surge Toward Alfasigma Acquisition PriceSeptember 26, 2023 | marketwatch.comIntercept Pharmaceuticals’ stock set to soar after Alfasigma buyout deal for an 82% premiumSeptember 26, 2023 | msn.comItaly's Alfasigma to buy drugmaker Intercept for nearly $800 mlnSeptember 26, 2023 | reuters.comAlfasigma To Acquire Intercept Pharma Fo $19 Per Share In CashSeptember 26, 2023 | markets.businessinsider.comWhy Is Rare Liver Disease Focused Intercept Pharmaceuticals Stock Trading Higher Today?September 26, 2023 | markets.businessinsider.comAlfasigma to Acquire Intercept Pharmaceuticals for $19.00 per Share in Cash, Expanding the Global Footprint of Alfasigma Via a Leader in Rare and Serious Liver DiseasesSeptember 26, 2023 | finance.yahoo.comUPDATE 2-Italy's Alfasigma to buy US liver disease drugmaker Intercept for nearly $800 mlnSeptember 26, 2023 | finance.yahoo.comIntercept Pharmaceuticals (Nasdaq:ICPT) HeadlineTrading was temporarily halted for "ICPT" at 07:09 AM with a stated reason of "News pending."...September 26, 2023 | marketbeat.comFY2025 EPS Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Lifted by Zacks ResearchSeptember 20, 2023 | marketbeat.comIntercept Pharma (ICPT) Receives a Hold from RBC CapitalSeptember 8, 2023 | markets.businessinsider.comWhy CymaBay Therapeutics Stock Is Jumping TodaySeptember 8, 2023 | finance.yahoo.comWhy Is Fate Therapeutics (FATE) Down 23.5% Since Last Earnings Report?September 7, 2023 | finance.yahoo.comCredit Suisse AG Has $1.71 Million Stock Holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)September 6, 2023 | marketbeat.comExodusPoint Capital Management LP Has $1.04 Million Stock Holdings in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)September 5, 2023 | marketbeat.comWhy Is Intercept (ICPT) Up 0.6% Since Last Earnings Report?September 1, 2023 | finance.yahoo.comLeerink Partnrs Equities Analysts Lift Earnings Estimates for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)August 28, 2023 | marketbeat.comIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares Acquired by Pictet Asset Management SAAugust 23, 2023 | marketbeat.comIntercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Shares Bought by Mirae Asset Global Investments Co. Ltd.August 22, 2023 | marketbeat.comQ3 2023 Earnings Forecast for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Issued By Zacks ResearchAugust 21, 2023 | marketbeat.comZacks Research Weighs in on Intercept Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ICPT)August 18, 2023 | marketbeat.com Get Intercept Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ICPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ICPT Media Mentions By Week ICPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ICPT News Sentiment▼0.301.03▲Average Medical News Sentiment ICPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ICPT Articles This Week▼00▲ICPT Articles Average Week Get the Latest News and Ratings for ICPT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Intercept Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies LGND News Today FOLD News Today BCRX News Today CLDX News Today NVAX News Today INVA News Today MNKD News Today DVAX News Today OPK News Today GERN News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ICPT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intercept Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intercept Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access